Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U10HD036790 | U.S. NIH Grant/Contract | View source | |
| U10HD021364 | U.S. NIH Grant/Contract | View source | |
| U10HD021373 | U.S. NIH Grant/Contract | View source | |
| U10HD021385 | U.S. NIH Grant/Contract | View source | |
| U10HD027851 | U.S. NIH Grant/Contract | View source | |
| U10HD027853 | U.S. NIH Grant/Contract | View source | |
| U10HD027856 | U.S. NIH Grant/Contract | View source | |
| U10HD027871 | U.S. NIH Grant/Contract | View source | |
| U10HD027880 | U.S. NIH Grant/Contract | View source | |
| U10HD027904 | U.S. NIH Grant/Contract | View source | |
| U10HD034216 | U.S. NIH Grant/Contract | View source | |
| U10HD040492 | U.S. NIH Grant/Contract | View source | |
| U10HD040689 | U.S. NIH Grant/Contract | View source | |
| U10HD053089 | U.S. NIH Grant/Contract | View source | |
| U10HD053109 | U.S. NIH Grant/Contract | View source | |
| U10HD053119 | U.S. NIH Grant/Contract | View source | |
| U10HD053124 | U.S. NIH Grant/Contract | View source | |
| UL1RR024139 | U.S. NIH Grant/Contract | View source | |
| UL1RR025744 | U.S. NIH Grant/Contract | View source | |
| UL1RR024979 | U.S. NIH Grant/Contract | View source | |
| U10HD068244 | U.S. NIH Grant/Contract | View source | |
| 1U10HD068263-01 | U.S. NIH Grant/Contract | View source | |
| U10HD068270 | U.S. NIH Grant/Contract | View source | |
| U10HD068278 | U.S. NIH Grant/Contract | View source | |
| U10HD068284 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Center for Research Resources (NCRR) | NIH |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a randomized, placebo-controlled, clinical trial to evaluate whether induced whole-body hypothermia initiated between 6-24 hours of age and continued for 96 hours in infants ≥ 36 weeks gestational age with hypoxic-ischemic encephalopathy will reduce the incidence of death or disability at 18-22 months of age. The study will enroll 168 infants with signs of hypoxic-ischemic encephalopathy at 16 NICHD Neonatal Research Network sites, and randomly assign them to either receive hypothermia or participate in a non-cooled control group.
Hypoxic-ischemic encephalopathy (HIE) is a rare, but life-threatening condition characterized by acute or subacute brain injury due to asphyxia. In most cases the underlying cause and timing of injury are unknown, but many cases are diagnosed at or shortly after birth.
According to the World Health Organization, more than 722,000 children died from birth asphyxia and birth trauma worldwide in 2004. An estimated 50-75 percent of infants with severe (stage 3) HIE will die, with 55 percent of these deaths occurring in the first month.
The incidence of long-term complications depends on the severity of HIE. Up to 80 percent of infants who survive stage 3 HIE develop significant long-term neurological disabilities - mental retardation, epilepsy, and cerebral palsy with hemiplegia, paraplegia, or quadriplegia; 10-20 percent develop moderately serious disabilities; and up to 10 percent are normal.
Because animal data suggests that brain injury from HIE evolves over several hours to days after the initial asphyxic insult, induced hypothermia holds promise as a neuroprotective therapy. Additional trials are needed to help define the most effective cooling strategies.
With this in mind, and knowing that many babies with HIE arrive at neonatal intensive care units several hours after birth, this study will evaluate the safety and efficacy of initiating hypothermia 6-24 hours after birth.
Study subjects: Infants born at 36 0/7ths weeks or greater gestational age that have been diagnosed with neonatal depression, perinatal asphyxia, or encephalopathy. The goal is to enroll 168 subjects.
Stratification: After informed consent is obtained, infants will be randomized to either a hypothermia arm (with a target esophageal temperature of 33.5°C) or a control arm (37.0°C) for 96 hours. Enrolled infants will be stratified by age of enrollment (≤ 12 and > 12 hours) and stage of encephalopathy (moderate or severe).
Informed Consent: Parents of eligible infants will be approached for consent to enroll in the study if the infant has a high probability of acute hemodynamic compromise, as defined above. Subsequent screening will determine whether the infant meets all inclusion criteria.
Randomization: eligible and consented infants will be randomly assigned to either a hypothermia intervention group, or a non-cooled (control) group.
Study Intervention: Induced whole-body hypothermia (with a target esophageal temperature of 33.5°C) or a control group (37.0°C) for 96 hours.
Interim Study Interruptions: None to date.
Secondary Study includes determining an association between MRI detectable injury and neurodevelopment at 18-22 months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Whole-body Hypothermia | Experimental | Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours |
|
| Normothermia | Active Comparator | Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hypothermia | Procedure | Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours |
|
| Measure | Description | Time Frame |
|---|---|---|
| Death or Moderate or Severe Disability | Severe disability was defined by any of the following: a Bayley III cognitive score < 70 or Gross Motor Functional (GMF) Level of 3-5 blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. | Birth to 18-22 months corrected gestational age |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Deaths in the NICU and Following Discharge | Birth to 18-22 months corrected gestational age | |
| Number of Infants With Moderate and Severe Disability | Moderate disability will be defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score < 70 or Gross Motor Functional (GMF) Level of 3-5 or blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. |
Not provided
Inclusion Criteria:
Infants born at 36 0/7ths weeks gestational age or greater (by best obstetrical estimate)
Postnatal age between 6 and 24 hours following birth
Infants with a high probability of acute hemodynamic compromise, such as those with:
Infants matching the above criteria who also have an abnormal neurological exam showing the presence of moderate or severe encephalopathy
Infants whose parents/legal guardians have provided consent for enrollment.
NOTE: These inclusion criteria are identical to the NICHD Neonatal Research Network's 2005 Hypothermia study (see links below), except for the time of entry (6-24 hours vs. < 6 hours of age).
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Abbot R. Laptook, MD | Brown University, Women & Infants Hospital of Rhode Island | Principal Investigator |
| Michele C. Walsh, MD MS | Case Western Reserve University, Rainbow Babies and Children's Hospital | Principal Investigator |
| Ronald N. Goldberg, MD | Duke University | Principal Investigator |
| Barbara J. Stoll, MD | Emory University | Principal Investigator |
| Brenda B. Poindexter, MD MS | Indiana University | Principal Investigator |
| Abhik Das, PhD | RTI International | Principal Investigator |
| Krisa P. Van Meurs, MD | Stanford University | Principal Investigator |
| Ivan D. Frantz III, MD | Tufts Medical Center | Principal Investigator |
| Kurt Schibler, MD | Children's Hospital Medical Center, Cincinnati | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | United States | ||
| University of California - Los Angeles |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35835616 | Derived | Bonifacio SL, Chalak LF, Van Meurs KP, Laptook AR, Shankaran S. Neuroprotection for hypoxic-ischemic encephalopathy: Contributions from the neonatal research network. Semin Perinatol. 2022 Nov;46(7):151639. doi: 10.1016/j.semperi.2022.151639. Epub 2022 Jun 10. | |
| 33189747 | Derived | Laptook AR, Shankaran S, Barnes P, Rollins N, Do BT, Parikh NA, Hamrick S, Hintz SR, Tyson JE, Bell EF, Ambalavanan N, Goldberg RN, Pappas A, Huitema C, Pedroza C, Chaudhary AS, Hensman AM, Das A, Wyckoff M, Khan A, Walsh MC, Watterberg KL, Faix R, Truog W, Guillet R, Sokol GM, Poindexter BB, Higgins RD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Limitations of Conventional Magnetic Resonance Imaging as a Predictor of Death or Disability Following Neonatal Hypoxic-Ischemic Encephalopathy in the Late Hypothermia Trial. J Pediatr. 2021 Mar;230:106-111.e6. doi: 10.1016/j.jpeds.2020.11.015. Epub 2020 Nov 13. |
| Label | URL |
|---|---|
| NICHD Neonatal Research Network | View source |
Not provided
Not provided
Multicenter randomized trial to evaluate whether induced hypothermia with body cooling initiated between 6-24 hours of age and continued for 96 hours in infants >= 36 weeks gestation with hypoxic-ischemic encephalopathy will reduce the incidence of death or disability at 18 months of age. Eligible infants were enrolled from 05/06/08 to 07/12/14.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Whole-body Hypothermia | Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours |
| FG001 | Normothermia | Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Normothermic Control | Procedure | Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours |
|
| Birth to 18-22 months corrected gestational age |
| Number of Infants With Mild, Moderate and Severe Disability | Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score >= 85 and any of the following: presence of a GMF level 1 or 2 OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score < 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. | Birth to 18-22 months corrected gestational age |
| Number of Infants With Any Disability Based on Level of Encephalopathy at Randomization | Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score >= 85 and any of the following: presence of a GMF level 1 or 2OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score < 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. | Birth to 18-22 months corrected gestational age |
| Number of Infants With Non-CNS Organ System Dysfunction | Based on observing presence of organ dysfunction on at least one of the following: Pulmonary (Meconium aspiration syndrome, PPHN, Pulmonary hemorrhage, Pneumonia, Chronic lung disease, ECMO, INO), Cardiovascular (Cardiomegaly, Cardiac failure, Cardiac dysfunction (by echo), Cardiac ischemia (by EKG and/or increased enzymes), Hypotension, Arrhythmia), Renal (Oliguria, Anuria, Dialysis), Gastrointestinal (NEC, Hepatic dysfunction), Hematologic (DIC) and Metabolic (Hypoglycemia, Hypocalcemia, Hypomagnesemia) | Birth to 18-22 months corrected gestational age |
| Number of Infants With a DNR Order | Birth to 18-22 months corrected gestational age |
| Number of Infants With a DNR Order and Support is Withdrawn | Birth to 18-22 months corrected gestational age |
| Number of Infants With a DNR Order That Died | Birth to 18-22 months corrected gestational age |
| Number of Infants With Neonatal Seizures, With and Without EEG Abnormalities | Birth to 18-22 months corrected gestational age |
| Waldemar A. Carlo, MD |
| University of Alabama at Birmingham |
| Principal Investigator |
| Edward F. Bell, MD | University of Iowa | Principal Investigator |
| Kristi L. Watterberg, MD | University of New Mexico | Principal Investigator |
| Myra Wyckoff, MD | University of Texas, Southwestern Medical Center at Dallas | Principal Investigator |
| Kathleen A. Kennedy, MD MPH | The University of Texas Health Science Center, Houston | Principal Investigator |
| Roger G. Faix, MD | University of Utah | Principal Investigator |
| Seetha Shankaran, MD | Wayne State University | Principal Investigator |
| Richard A. Ehrenkranz, MD | Yale University | Principal Investigator |
| William Truog, MD | Children's Mercy Hospital Kansas City | Principal Investigator |
| Barbara Schmidt, MD, MSc | University of Pennsylvania | Principal Investigator |
| Carl D'Angio, MD | University of Rochester | Principal Investigator |
| Uday Devaskar, MD | University of California, Los Angeles | Principal Investigator |
| Pablo Sanchez, M.D | Ohio State University | Principal Investigator |
| Los Angeles |
| California |
| 90025 |
| United States |
| Stanford University | Palo Alto | California | 94304 | United States |
| Yale University | New Haven | Connecticut | 06504 | United States |
| Emory University | Atlanta | Georgia | 30303 | United States |
| Indiana University | Indianapolis | Indiana | 46202 | United States |
| University of Iowa | Iowa City | Iowa | 52242 | United States |
| Tufts Medical Center | Boston | Massachusetts | 02111 | United States |
| Wayne State University | Detroit | Michigan | 48201 | United States |
| Children's Mercy Hospital | Kansas City | Missouri | 64108 | United States |
| University of New Mexico | Albuquerque | New Mexico | 87131 | United States |
| University of Rochester | Rochester | New York | 14642 | United States |
| RTI International | Durham | North Carolina | 27705 | United States |
| Duke University | Durham | North Carolina | 27710 | United States |
| Cincinnati Children's Medical Center | Cincinnati | Ohio | 45267 | United States |
| Case Western Reserve University, Rainbow Babies and Children's Hospital | Cleveland | Ohio | 44106 | United States |
| Research Institute at Nationwide Children's Hospital | Columbus | Ohio | 43205 | United States |
| Univeristy of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| Brown University, Women & Infants Hospital of Rhode Island | Providence | Rhode Island | 02905 | United States |
| University of Texas Southwestern Medical Center at Dallas | Dallas | Texas | 75235 | United States |
| University of Texas Health Science Center at Houston | Houston | Texas | 77030 | United States |
| University of Utah | Salt Lake City | Utah | 84108 | United States |
| 29067428 | Derived | Laptook AR, Shankaran S, Tyson JE, Munoz B, Bell EF, Goldberg RN, Parikh NA, Ambalavanan N, Pedroza C, Pappas A, Das A, Chaudhary AS, Ehrenkranz RA, Hensman AM, Van Meurs KP, Chalak LF, Khan AM, Hamrick SEG, Sokol GM, Walsh MC, Poindexter BB, Faix RG, Watterberg KL, Frantz ID 3rd, Guillet R, Devaskar U, Truog WE, Chock VY, Wyckoff MH, McGowan EC, Carlton DP, Harmon HM, Brumbaugh JE, Cotten CM, Sanchez PJ, Hibbs AM, Higgins RD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Effect of Therapeutic Hypothermia Initiated After 6 Hours of Age on Death or Disability Among Newborns With Hypoxic-Ischemic Encephalopathy: A Randomized Clinical Trial. JAMA. 2017 Oct 24;318(16):1550-1560. doi: 10.1001/jama.2017.14972. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Whole-body Hypothermia | Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours |
| BG001 | Normothermia | Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Age at Randomization | Count of Participants | Participants |
| ||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||
| Level of Encephalopathy | Count of Participants | Participants |
| |||||||||||||||||||
| Birthweight | Mean | Standard Deviation | grams |
| ||||||||||||||||||
| Length | Mean | Standard Deviation | centimeters |
| ||||||||||||||||||
| Gestational Age | Mean | Standard Deviation | weeks |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Death or Moderate or Severe Disability | Severe disability was defined by any of the following: a Bayley III cognitive score < 70 or Gross Motor Functional (GMF) Level of 3-5 blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. | Does not include 9 lost to follow up and 2 infants without outcome for behavior issues | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Deaths in the NICU and Following Discharge | Does not include 9 lost to follow up and 2 infants without outcome for behavior issues | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Infants With Moderate and Severe Disability | Moderate disability will be defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score < 70 or Gross Motor Functional (GMF) Level of 3-5 or blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. | Does not include 9 lost to follow up and 2 infants without outcome for behavior issues | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Infants With Mild, Moderate and Severe Disability | Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score >= 85 and any of the following: presence of a GMF level 1 or 2 OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score < 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. | Does not include 9 lost to follow up and 2 infants without outcome for behavior issues | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Infants With Any Disability Based on Level of Encephalopathy at Randomization | Mild disability will be defined by either a Bayley III cognitive score of 70-84 alone or a Bayley III cognitive score >= 85 and any of the following: presence of a GMF level 1 or 2OR seizure disorder or hearing loss. Moderate disability was defined as a Bayley III cognitive score between 70-84 and either a GMF level of 2 or a seizure disorder or a hearing deficit. Severe disability will be defined by any of the following: a Bayley III cognitive score < 70 OR Gross Motor Functional (GMF) Level of 3-5 OR blindness or profound hearing loss requiring amplification but still unable to follow commands/communicate. | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Infants With Non-CNS Organ System Dysfunction | Based on observing presence of organ dysfunction on at least one of the following: Pulmonary (Meconium aspiration syndrome, PPHN, Pulmonary hemorrhage, Pneumonia, Chronic lung disease, ECMO, INO), Cardiovascular (Cardiomegaly, Cardiac failure, Cardiac dysfunction (by echo), Cardiac ischemia (by EKG and/or increased enzymes), Hypotension, Arrhythmia), Renal (Oliguria, Anuria, Dialysis), Gastrointestinal (NEC, Hepatic dysfunction), Hematologic (DIC) and Metabolic (Hypoglycemia, Hypocalcemia, Hypomagnesemia) | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Infants With a DNR Order | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Infants With a DNR Order and Support is Withdrawn | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Infants With a DNR Order That Died | Only infants with DNR order | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Infants With Neonatal Seizures, With and Without EEG Abnormalities | Posted | Count of Participants | Participants | Birth to 18-22 months corrected gestational age |
|
|
During study intervention period: 124 hours from baseline (time of insertion of esophageal probe).
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Whole-body Hypothermia | Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours | 6 | 83 | 5 | 83 | 0 | 83 |
| EG001 | Normothermia | Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours | 5 | 85 | 1 | 85 | 0 | 85 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Bleeding | Vascular disorders | Systematic Assessment |
| ||
| Alteration of skin integrity | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| PPHN/Acidosis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
Not provided
Investigators must adhere to the Neonatal Research Network Publication policies.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Abbot Laptook | Brown University, Women & Infants Hospital of Rhode Island | 401-274-1122 | 47421 | alaptook@wihri.org |
| ID | Term |
|---|---|
| D002534 | Hypoxia, Brain |
| D020925 | Hypoxia-Ischemia, Brain |
| D007035 | Hypothermia |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D000860 | Hypoxia |
| D012818 | Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D002545 | Brain Ischemia |
| D002561 | Cerebrovascular Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001832 | Body Temperature Changes |
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| Male |
|
| Severe |
|
This trial estimated the probability that the intervention has no effect on the outcome (or conversely, the probability that it does), given the data obtained in the trial and any prior evidence. |
We fitted all Bayesian models via Markov chain Monte Carlo methods (MCMC) using JAGS (version 3.4) and OpenBUGS (3.2.3) in R (version 3.2.5). For each analysis we ran 3 MCMC chains with starting values randomly drawn from the estimated parameters from a frequentist log binomial model. A burn-in of 1,000 iterations was used, with sampling from a further 10,000 iterations for each chain. To monitor convergence, trace plots and the Gelman-Rubin convergence diagnostic (Rhat) were used for all parameters. For all analyses, the trace plots show good mixing of the 3 chains with Rhat < 1.01 for all parameters, indicating convergence. |
|
|
| Participants |
|
|
|
|
|
|
|
|